Pengyan Fa
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
27
Citations
210
Est. group size
—
Recurring co-author estimate
Active years
12
Publishing since 2015
Pengyan Fa's research focuses on the molecular biology of cancer, examining how DNA repair, cell cycle control, and protein regulation pathways (such as PP2A, RNF126, and SPEN) influence cancer development, prognosis, and drug response. Recent work spans diffuse large B-cell lymphoma, breast cancer, lung cancer, and renal cell carcinoma, with particular attention to biomarkers that predict sensitivity to DNA-damage-targeting drugs (like ATR and CHK1 inhibitors) and to immune-related mechanisms in cancer, including neutrophil extracellular traps and immune evasion.
Publication output was low and steady (about one paper per year) from 2018-2022, then spiked sharply in 2023 with a large cluster of related papers and supplementary datasets, followed by a smaller but continued output through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- <i>SPEN</i> Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Cancer Discovery · 2026
- Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities
Blood · 2025
- Spen loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities
Blood · 2025
- PP2A B55α inhibits epithelial-mesenchymal transition via regulation of Slug expression in non-small cell lung cancer
Cancer Letters · 2024
- The implication of neutrophil extracellular traps in nonalcoholic fatty liver disease
Frontiers in Immunology · 2023
- Neutrophils Extracellular Traps (NETs) Inhibition Improves PD-1 Blockade Immunotherapy in Triple-Negative Breast Cancer
The Journal of Immunology · 2023
- Data from A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors
2023
- Data from A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors
2023
- Supplementary Data from A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors
2023
- Supplementary Data from A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors
2023
- Supplementary from RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells
2023
- Supplementary Data from A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors
2023
- Supplementary Data from A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors
2023
- Supplementary from RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells
2023
- Data from RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells
2023
- Blood×2
- Frontiers in Immunology×1
- Clinical Cancer Research×1
- Cancer Research×1
- Journal of Biological Chemistry×1
- Zhaojun Qiu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Chandra Bhushan Prasad
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jiaxing Miao
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Joseph Mills
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Chittaranjan Das
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile